117 related articles for article (PubMed ID: 1658605)
1. Inhibition of eukaryotic DNA topoisomerase I and II activities by indoloquinolinedione derivatives.
Riou JF; Helissey P; Grondard L; Giorgi-Renault S
Mol Pharmacol; 1991 Nov; 40(5):699-706. PubMed ID: 1658605
[TBL] [Abstract][Full Text] [Related]
2. Identification of topoisomerase I as the cytotoxic target of the protoberberine alkaloid coralyne.
Gatto B; Sanders MM; Yu C; Wu HY; Makhey D; LaVoie EJ; Liu LF
Cancer Res; 1996 Jun; 56(12):2795-800. PubMed ID: 8665516
[TBL] [Abstract][Full Text] [Related]
3. Quantitative and qualitative aspects of topoisomerase I and II alpha and beta in untreated and platinum/cyclophosphamide treated malignant ovarian tumors.
van der Zee AG; de Jong S; Keith WN; Hollema H; Boonstra H; de Vries EG
Cancer Res; 1994 Feb; 54(3):749-55. PubMed ID: 8306337
[TBL] [Abstract][Full Text] [Related]
4. Intoplicine (RP 60475) and its derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities.
Riou JF; Fossé P; Nguyen CH; Larsen AK; Bissery MC; Grondard L; Saucier JM; Bisagni E; Lavelle F
Cancer Res; 1993 Dec; 53(24):5987-93. PubMed ID: 8261412
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory activities against topoisomerase I and II by isoaurostatin derivatives and their structure-activity relationships.
Suzuki K; Okawara T; Higashijima T; Yokomizo K; Mizushima T; Otsuka M
Bioorg Med Chem Lett; 2005 Apr; 15(8):2065-8. PubMed ID: 15808469
[TBL] [Abstract][Full Text] [Related]
6. A new mechanism of acquisition of drug resistance by partial duplication of topoisomerase I.
Komatani H; Morita M; Sakaizumi N; Fukasawa K; Yoshida E; Okura A; Yoshinari T; Nishimura S
Cancer Res; 1999 Jun; 59(11):2701-8. PubMed ID: 10363995
[TBL] [Abstract][Full Text] [Related]
7. Topoisomerase I/II selectivity among derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).
Bridewell DJ; Finlay GJ; Baguley BC
Anticancer Drug Des; 2001 Dec; 16(6):317-24. PubMed ID: 12375884
[TBL] [Abstract][Full Text] [Related]
8. DNA topoisomerases I and II in human mature sperm cells: characterization and unique properties.
Har-Vardi I; Mali R; Breietman M; Sonin Y; Albotiano S; Levitas E; Potashnik G; Priel E
Hum Reprod; 2007 Aug; 22(8):2183-9. PubMed ID: 17656417
[TBL] [Abstract][Full Text] [Related]
9. Effects of morpholinyl doxorubicins, doxorubicin, and actinomycin D on mammalian DNA topoisomerases I and II.
Wassermann K; Markovits J; Jaxel C; Capranico G; Kohn KW; Pommier Y
Mol Pharmacol; 1990 Jul; 38(1):38-45. PubMed ID: 2164630
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and antiproliferative evaluation of certain indeno[1,2-c]quinoline derivatives. Part 2.
Tseng CH; Tzeng CC; Yang CL; Lu PJ; Chen HL; Li HY; Chuang YC; Yang CN; Chen YL
J Med Chem; 2010 Aug; 53(16):6164-79. PubMed ID: 20662543
[TBL] [Abstract][Full Text] [Related]
11. Modulation of 4'-(9-acridinylamino)methanesulfon-m-anisidide-induced, topoisomerase II-mediated DNA cleavage by gossypol.
Adlakha RC; Ashorn CL; Chan D; Zwelling LA
Cancer Res; 1989 Apr; 49(8):2052-8. PubMed ID: 2539251
[TBL] [Abstract][Full Text] [Related]
12. Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II.
Adjei AA; Charron M; Rowinsky EK; Svingen PA; Miller J; Reid JM; Sebolt-Leopold J; Ames MM; Kaufmann SH
Clin Cancer Res; 1998 Mar; 4(3):683-91. PubMed ID: 9533538
[TBL] [Abstract][Full Text] [Related]
13. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
14. A novel use for the comet assay: detection of topoisomerase II inhibitors.
Salti GI; Das Gupta TK; Constantinou AI
Anticancer Res; 2000; 20(5A):3189-93. PubMed ID: 11062742
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity study of the interaction of bioreductive benzoquinone alkylating agents with DNA topoisomerase II.
Hasinoff BB; Wu X; Begleiter A; Guziec LJ; Guziec F; Giorgianni A; Yang S; Jiang Y; Yalowich JC
Cancer Chemother Pharmacol; 2006 Jan; 57(2):221-33. PubMed ID: 16010589
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, topoisomerase I inhibitory activity and in vitro cytotoxicity of camptothecin derivatives bearing five-membered heterocycle containing 10-substituents.
Zhao R; Guan LL; Oreski B; Lown JW
Anticancer Drug Des; 1998 Mar; 13(2):145-57. PubMed ID: 9524556
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan.
Liebes L; Potmesil M; Kim T; Pease D; Buckley M; Fry D; Cho J; Adler H; Dar K; Zeleniuch-Jacquotte A; Hochster H
Clin Cancer Res; 1998 Mar; 4(3):545-57. PubMed ID: 9533521
[TBL] [Abstract][Full Text] [Related]
18. Effect of yerba mate (Ilex paraguariensis) tea on topoisomerase inhibition and oral carcinoma cell proliferation.
Gonzalez de Mejia E; Song YS; Ramirez-Mares MV; Kobayashi H
J Agric Food Chem; 2005 Mar; 53(6):1966-73. PubMed ID: 15769122
[TBL] [Abstract][Full Text] [Related]
19. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content.
Eng WK; McCabe FL; Tan KB; Mattern MR; Hofmann GA; Woessner RD; Hertzberg RP; Johnson RK
Mol Pharmacol; 1990 Oct; 38(4):471-80. PubMed ID: 2172765
[TBL] [Abstract][Full Text] [Related]
20. BN80927: a novel homocamptothecin that inhibits proliferation of human tumor cells in vitro and in vivo.
Demarquay D; Huchet M; Coulomb H; Lesueur-Ginot L; Lavergne O; Camara J; Kasprzyk PG; Prévost G; Bigg DC
Cancer Res; 2004 Jul; 64(14):4942-9. PubMed ID: 15256467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]